New drug FXS5626 put to the test: will it affect the Heart's rhythm?
NCT ID NCT07695779
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study investigates the safety and tolerability of a single oral dose of FXS5626 in healthy Chinese adults aged 18 to 45. Researchers will measure how the drug affects the heart's electrical activity (QT interval) and look for any side effects. The goal is to understand the drug's behavior in the body before moving to larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FXS5626 tablet
- What this could lead to
- If safe, this could support further studies of FXS5626 for potential future uses.
- What could go wrong
- This is an early Phase 1 trial with only 28 healthy people, so it cannot predict real-world benefits or risks. The drug may cause unexpected side effects or heart rhythm changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EVALUATION OF QTC INTERVAL are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China